CStone Announces China NMPA New Drug Approval of Precision Therapy AYVAKIT® (avapritinib) for the Treatment of Adults with Unresectable or Metastatic PDGFRA Exon 18 Mutant Gastrointestinal Stromal Tumor

CStone Pharmaceuticals Reports Financial Results and Business Highlights for Full-year 2020

CStone Announces New Drug Approval of GAVRETO® (pralsetinib) as First Selective RET Inhibitor in China, Providing a New Therapy for a Subset of Non-Small Cell Lung Cancer Patients

CStone Announces Another Breakthrough Therapy Designation Granted for Sugemalimab, Representing a New Breakthrough in the Treatment of Relapsed and Refractory Lymphoma

CStone Pharmaceuticals Reports Efficacy and Safety Data from the ARROW Trial of Pralsetinib in Chinese Patients with Advanced RET Fusion-positive Non-Small Cell Lung Cancer after Platinum-based Chemotherapy at IASLC WCLC 2020

CStone’s Partner Blueprint Medicines Announces U.S. FDA Approval of GAVRETO™ (pralsetinib) for the Treatment of Patients with Advanced or Metastatic RET-Mutant and RET Fusion-Positive Thyroid Cancer

ESMO ASIA Congress 2020| CStone Pharmaceuticals announces the results of GEMSTONE-302, Sugemalimab has the potential to provide a new treatment option for patients with advanced NSCLC

Global Strategic Partnership Between CStone and EQRx Takes Effect Following Early Termination of HSR Waiting Period

CStone Pharmaceuticals Announces China’s NMPA has Accepted its New Drug Application for anti-PD-L1 Monoclonal Antibody Sugemalimab in First-Line Advanced NSCLC

CStone Successfully Submitted an NDA for Ivosidenib in Singapore, for IDH1-mutated Relapsed or Refractory Acute Myeloid Leukemia